On 6 April 2020, Mateon Therapeutics Inc. committed to developing OT-101, a transforming growth factor beta (TGF-β) antisense medicine candidate, and stated that this treatment could be utilized to treat COVID-19 [91]. Here, TGFB1 is linked to COVID-19.